IsoPlexis is empowering the ability to combine immunotherapies from discovery through the entire translational process
Checkpoint & Combination Immunotherapy
Join us to learn more about how we are accelerating immunotherapy programs across the discover-optimize-predict continuum with our unique cellular analysis metrics
IsoPlexis' systems are revealing choice in novel bispecific development targeting the tumor microenvironment
IsoPlexis' PSITM helps uncover the T cell mechanism of agonists used in combination with reengineered cell therapies
Our systems are able to uniquely stratify patient response in solid tumor based on TIL polyfunction
on our datasets >[/ce_button]
Single-cell proteomic analysis of T cells stimulated by Bi-specific T cell Engagers shows a robust and unique polyfunctional secretion profile. Mackay S, Paczkowski P, Flynn B, Morse K, Liu D, Coupet TA, Godbersen C, Sentman CL, Zhou J. Presented at SITC Annual Meeting 2018.
Intratumoral (IT) injection of the toll-like receptor 4 (TLR4) agonist G100 induces a clinical response and a T cell response locally and systemically. Seo YD, Zhou J, Morse K, Patino J, Mackay S, Kim EY, Conrad III EU, O'Malley RB, Cranmer L, Lu H, Hsu FJ, Xu Y, Loggers E, Hain T, Pillarisetty VG, Kane G, Riddell S, Meulen J, Jones RL, Pollack SM. Journal of Clinical Oncology, 36, Suppl 5S (2018).
Enhanced Expansion and Tumor Targeting of Adoptively Transferred T Cells with NKTR-214. Parisi G, Saco J, Salazar F, Krystofinski P, Tsoi J, Zhang R, Puig Saus C, Zhou J, Hu-Lieskovan S, Comin-Anduix B, Wu A, Charych DH, Ribas A. Session PO.CL06.03 - Adoptive Cell Therapy 3. American Association for Cancer Research Annual Meeting 2018.
Single-cell PSI of CD8+ TILs in melanoma shows uniquely sensitive correlates with response to anti-PD-1/CTLA4 therapy, where histology and serum cytokines were unable to detect significant associations. Mackay S, Flynn B, Morse K, Paczkowski P, Chen J, Liu D, Bacchiocchi A, Heath JR, Fan R, Sznol M, Halaban R, Zhou J. Presented at SITC Annual Meeting 2018.
Single-Cell Cytokine Profiling of Tumor-Infiltrating T Cells to Measure Patient Responses to Anti-PD-1 Therapy. Mackay S, Flynn B, Morse K, Paczkowski P, Bacchiocchi A, Heath JR, Fan R, Halaban R, and Zhou J. Presented at TRCCC Annual Meeting 2018.
Single-Cell Cytokine Profiling of Tumor-Infiltrating T Cells to Measure Patient Responses to Anti-PD-1 Therapy. Mackay S, Flynn B, Morse K, Paczkowski P, Bacchiocchi A, Fan R, Halaban R, and Zhou J. Journal of Clinical Oncology, 35 (9), Suppl. 7S (2017).